BIOMAT Database Logo BIOMAT Database Logo

Growth hormone and somatostatin gene expression in pituitary adenomas with active acromegaly and minimal plasma growth hormone elevation. 1990

P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
INSERM U. 223, Faculté de Médecine Pitié-Salpêtrière, Paris, France.

Some patients with active acromegaly have elevated plasma IGF-I concentrations with only minimal elevation of plasma GH. We compared adenomatous GH and SRIH expression in 3 such patients (patients No. 1, 2 and 3; basal plasma GH level less than 4 micrograms/l) and in 3 acromegalic patients with high basal plasma GH level (patients No. 4, 5 and 6; 51.7 +/- 16.1 micrograms/l, mean +/- SEM). By immunocytochemistry, all the tumours proved to be somatotropic adenomas. At the ultrastructural level, signs of low secretory activity were observed in adenomas from patients No. 2 and 3. Perifused adenoma cells of patients No. 1, 2 and 3 released very little GH compared with those of patients No. 4, 5 and 6 (1 +/- 0.37 vs 51.5 +/- 34.1 micrograms x (10(-6) cells) x min-1, p less than 0.001). Adenoma SRIH content was 65.7 and 30.6 pg/mg proteins in patients No. 1 and 2, whereas it was undetectable in the others (patients No. 4, 5 and 6). Northern blot analysis showed that the GH gene was poorly expressed in the adenomas from patients No. 1, 2 and 3 compared with the adenomas from patients No. 4, 5 and 6. SRIH mRNA was detected in all 6 adenomas. However, the signal was more intense in the adenomas from patients No. 1, 2 and 3 than in those from patients No. 4, 5 and 6.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
[Cushing's disease and acromegaly. Treatment of hormone active pituitary adenomas].
January 1992, Deutsche Krankenpflegezeitschrift,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Somatostatin receptor subtype gene expression in pituitary adenomas.
April 1995, The Journal of clinical endocrinology and metabolism,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Prolactin gene expression in human growth hormone-secreting pituitary adenomas.
June 1990, Journal of neurosurgery,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Characterization of growth hormone-releasing hormone receptors in pituitary adenomas from patients with acromegaly.
June 1988, The Journal of clinical endocrinology and metabolism,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas.
July 1985, The Journal of clinical endocrinology and metabolism,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
The size of growth hormone granules in pituitary adenomas producing acromegaly.
March 1977, Acta endocrinologica,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas.
August 1998, The Journal of clinical endocrinology and metabolism,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients.
April 1986, The Journal of clinical endocrinology and metabolism,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.
April 2003, Endocrine,
P Pagesy, and J Y Li, and F Rentier-Delrue, and O Delalande, and Y Le Bouc, and M Kujas, and D Joubert, and J Martial, and F Peillon
Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH.
October 1987, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!